Navigation Links
Cardiovascular Innovation Institute researchers receive over $2 million grant from NIH
Date:9/22/2010

Louisville, Ky. Researchers in the Cardiovascular Innovation Institute, a partnership between the University of Louisville and Jewish Hospital, in collaboration with researchers at Indiana University and Purdue University, have received a $2,027,059 grant from the National Institutes of Health to further develop an implantable pump that could dramatically improve the lives of patients with single ventricle heart disease. Single ventricle heart disease is a congenital condition in which one chamber of the heart is either missing or underdeveloped, causing an overwhelming burden on the remaining chamber to pump blood effectively.

The project is led by UofL biomedical engineer Guruprasad Giridharan, PhD, Indiana University pediatric surgeon Mark Rodefeld, MD, and Purdue University mechanical engineer Steve Frankel, PhD. It represents a collaboration between biomedical engineers in the Department of Bioengineering at UofL, who are based at the CII, and UofL's Division of Thoracic and Cardiovascular Surgery.

"Single ventricle heart disease is the leading cause of death from any birth defect in the first year of life," said Giridharan, who is UofL's principal investigator. "The children usually require three major surgeries in the first few years of life to re-route blood flow, and lighten the workload of the single ventricle, which pumps blood both to the body and lungs."

The implantable pump is designed to deliver blood to the lungs and assist the single ventricle, improving the child's circulatory status, Giridharan said.

"We have created pump prototypes of this novel and simple assist device," Giridharan said. "The funding from the NIH will enable improvement of the prototypes that will hopefully take it that much closer to implantation in humans."

This work has the potential to, at minimum, provide a crutch for patients who are undergoing the current treatment for this condition.

"This device has the pote
'/>"/>

Contact: Lauren Williams
lauren.williams@louisville.edu
502-852-7461
University of Louisville
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Significant weight-loss from surgery decreases risk for cardiovascular disease in women
2. EPA holds seminar on air pollution and cardiovascular disease
3. UH engineers to improve test for cardiovascular disease
4. CNIC and Banco Santander set up research project on early cardiovascular risk factors
5. New cancer therapy may fight cardiovascular disease
6. WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease
7. Shifting cellular energy metabolism may help treat cardiovascular disease
8. New nanoparticles target cardiovascular disease
9. Genetic analysis helps dissect molecular basis of cardiovascular disease
10. New study links vitamin D deficiency to cardiovascular disease and death
11. Columbia University Medical Center announces 2009 Katz Prizes in Cardiovascular Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... Calif. , Jan. 27, 2015 /PRNewswire/ ... provider of globally deployed, innovative test solutions ... announced the delivery of its TS-323 ... Space Systems Company (LMSSC). GENASYS is a ... demands of mission-critical applications that require performance ...
(Date:2/5/2015)...  It is gratifying to see that the Obama ... science as a means to better understand human biology, ... was honored to participate in today,s White House event ... Since the 1980s my teams have been ... sequenced genome of a free living organism, the first ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... Therapeutic hypothermia has been proven to reduce mortality and ... was rarely used in a sample of more than ... Hypothermia and Temperature Management, a peer-reviewed journal published by ... www.liebertpub.com/ther Therapeutic hyperthermia was used in ...
... The American Association of Anatomists, 2012 Basmajian Award will ... professor in the department of cell biology, neurobiology and ... ceremony will take place at the AAA Annual Meeting ... Marquis & Marina, San Diego, CA)., This award recognizes ...
... Life (EOL, www.eol.org ) continues to expand at a ... At the start of 2012, EOL provides data on nearly ... rich information about conservation issues from the International Union for ... and videos than ever before. In the four ...
Cached Biology News:Todd Hoagland honored by Anatomy Society for excellence in teaching, research & scholarship 2The Encyclopedia of Life expanding at a record pace 2
(Date:3/5/2015)... Conn. , March 5, 2015  UBM ... , a leading online community to help ... of the newest information available regarding the use ... of kidney cancer. March is ... are very few effective adjuvant treatment options for ...
(Date:3/5/2015)... 2015  In response to the incorrect assertions by ... on February 12, 2015. Impeto Medical SAS ... health and their SUDOSCAN® devices have been proven to ... prefers to have the courts decide this dispute rather ... 40 articles written by Key Opinion Leaders, published by ...
(Date:3/5/2015)... March 05, 2015 The next implants ... received the CE mark (European) approval. The CE mark ... Trade Association (EFTA) and the European Union. Following the ... been granted to implants supplied by the Turkey-based company ... , Osimplant's Cervical Expandable Bladed HA PEEK Cage ...
(Date:3/4/2015)... PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today ... , 3.75% Convertible Senior Notes due May 1, 2015 (May ... principal amount or approximately $5.72 per share, effective March 3, 2015. ... adjusted in connection with the regular quarterly dividend of $0.15 ... own shares of PDL on March 5, 2015, the record date. ...
Breaking Biology Technology:OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2
... First Clinical Milestone Validates Approach, SAN FRANCISCO, ... completion of its first clinical trial, a,proof-of-concept study ... sodium channel blocker. Rufinamide was discovered and,developed by ... Europe as a,drug to treat a form of ...
... January 22 Progentix,Orthobiology B.V. announced today the ... was led by BioGeneration Ventures., Progentix Orthobiology ... suite of osteoinductive material products for clinical application,in ... based on,surface structured ceramic biomaterial scaffolds that have ...
... year the NorTech Venture,Capital Advisory Task Force reported in ... need to generate and attract over $1.2 billion,in venture ... needs of companies,located in Northeast Ohio. According to the ... the Cleveland+ region, to be,released in print mid February, ...
Cached Biology Technology:Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 2Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 3Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 4Cleveland+ Region Attracts $318 Million in New Venture Investment in 2007 5
Mouse Wnt-11 Affinity Purified Polyclonal Ab...
...
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Use the DUALmembrane kit 3 to carry out DUALmembrane interaction analysis and cDNA library screening to characterize interactions between integral membrane proteins and to identify novel interaction ...
Biology Products: